Gilead Sciences

Bristol-Myers Ties Hepatitis C Success to Gilead’s Pill
Bloomberg
Tue, 01/14/14 - 09:15 am
hepatitis C
Gilead Sciences
Bristol-Myers Squibb
Sovaldi
declatasvir
FDA Accepts New Drug Application for Gilead’s Idelalisib for the Treatment of Refractory Indolent Non-Hodgkin’s Lymphoma
Yahoo
Mon, 01/13/14 - 09:41 am
FDA
Gilead Sciences
Idelalisib
refractory indolent non-Hodgkins lymphoma
Don't Underestimate Amgen: Part 1
Seeking Alpha
Fri, 01/10/14 - 08:37 am
Amgen
Celgene
Gilead Sciences
Biogen Idec
M&A Boom Seen in 2014 as Drug Hunt Spurs Biotech Deals
Bloomberg
Fri, 01/10/14 - 08:25 am
M&A
biotech
generics
Merck
Bristol-Myers Squibb
General Electric
Gilead Sciences
Thermo Fisher
Forest Labs
FDA
Acorda Therapeutics
Pfizer
JNJ
Roche
Pharmacyclics
Gilead Sales Chief Retires Amidst Key Hep C Drug Launch, Massive Insider Selling
TheStreet.com
Tue, 01/7/14 - 09:26 am
Gilead Sciences
hepatitis C
Sovaldi
22 Biotech Stock Predictions for 2014
TheStreet.com
Mon, 01/6/14 - 09:47 am
biotech
Vertex Pharmaceuticals
Orexigen
Retrophin
Valeant Pharmaceuticals
Questcor
Biomarin
Merck
NeoStem
Amgen
Gilead Sciences
Vanda
Keryx
Peregrine Pharmaceuticals
CelSci
Regeneron
Cempra
Dendreon
Clovis Oncology
Halozyme
NPS Pharmaceuticals
Pharmacyclics: As Imbruvica Commercialization Begins, Sell-Off Creates Opportunity
Seeking Alpha
Fri, 01/3/14 - 11:56 am
Pharmacyclics
Imbruvica
JNJ
Roche
Celgene
Gilead Sciences
mantle cell lymphoma
Gilead Seeks To Expand Its Blockbuster Hepatitis Platforms In 2014
Seeking Alpha
Fri, 01/3/14 - 11:41 am
Gilead Sciences
hepatitis C
Merck
Sovaldi
Vertex
Gilead Sciences: Sovaldi to Boost Shares in 2014, Maxim Group Says
Barron's
Thu, 01/2/14 - 11:28 am
Sovaldi
hepatitis C
Gilead Sciences
Grading Pharma In 2013: 16 Drug Companies Ranked
Forbes
Tue, 12/31/13 - 10:17 am
Bristol-Myers Squibb
Celgene
Gilead Sciences
Biogen Idec
AbbVie
Roche
JNJ
GSK
Amgen
Novo Nordisk
Pfizer
Novartis
Merck
Sanofi
AstraZeneca
Eli Lilly
Keep an Eye on These 3 Revolutionary Cancer Treatments in 2014
Motley Fool
Fri, 12/27/13 - 01:08 pm
cancer
Roche
Infinity Pharmaceuticals
Inovio
Immunogen
Gilead Sciences
immunotherapy
antibody-drug conjugate
Jim Cramer: Ride the Four Horsemen of Biotech
TheStreet.com
Fri, 12/27/13 - 09:34 am
biotech
Biogen Idec
Celgene
Gilead Sciences
Regeneron
This Week in Biotech
Motley Fool
Sun, 12/22/13 - 12:28 pm
GSK
Theravance
Ariad Pharmaceuticals
Gilead Sciences
AbbVie
Cubist Pharmaceuticals
Jazz Pharmaceuticals
Gentium
2 Big Biotechs Moving Up On News
Seeking Alpha
Fri, 12/20/13 - 12:58 pm
Jazz Pharmaceuticals
Gilead Sciences
Why Enanta Pharmaceuticals Shares Sank Like a Stone
Motley Fool
Thu, 12/19/13 - 08:08 am
Enanta
Sovaldi
Gilead Sciences
hepatitis C
ABT-450
AbbVie
Gilead to seek okay for combo hepatitis C pill in Q1
Reuters
Wed, 12/18/13 - 10:15 am
hepatitis C
Gilead Sciences
Sovaldi
ledipasvir
Ziopharm: Finally A Winner In The War On Cancer?
Seeking Alpha
Mon, 12/16/13 - 08:06 am
Ziopharm
cancer
AbbVie
Amgen
Celgene
Celldex Therapeutics
Gilead Sciences
Immunogen
JNJ
ImmunoCellular Therapeutics
Pharmacyclics
Intrexon
Seattle Genetics
Don't Short Gilead Sciences Just Yet
Seeking Alpha
Sat, 12/14/13 - 11:58 am
Gilead Sciences
Gilead Sciences' $1,000 Per Day Sovaldi Pills Ready to Launch
Motley Fool
Fri, 12/13/13 - 12:35 pm
Gilead Sciences
Sovaldi
drug launches
hepatitis C
Why Talk Of A Hepatitis C Price War Should Act As A Warning To The Pharma Industry-At-Large
Forbes
Wed, 12/11/13 - 08:34 am
hepatitis C
drug pricing
Gilead Sciences
Express Scripts

Pages